权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of CD46 theranostics for imaging and treatment of multiple myeloma

用于多发性骨髓瘤成像和治疗的 CD46 治疗诊断学的开发

基本信息

批准号：
10539684
负责人：
Robert Richard Flavell
金额：
$ 67.02万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10539684
关键词：
Animal Model Antibody-drug conjugates Antigens Award Binding Biodistribution CD46 Antigen CRISPR interference Cells Characteristics Chromosomes Clinical Trials Combined Modality Therapy Data Detection Development Disease Dose Eligibility Determination Epitopes Genes Genomics Goals Human Image Immunoglobulin G Isotopes Length Magnetic Resonance Imaging Malignant Neoplasms Maximum Tolerated Dose Methods Modeling Molecular Target Morbidity - disease rate Multiple Myeloma Mus PET/CT scan Patient Care Patients Performance Phase I Clinical Trials Physicians Pilot Projects Population Positron Positron-Emission Tomography Pre-Clinical Model Preclinical Testing Protocols documentation Radiolabeled Radionuclide therapy Radiopharmaceuticals Recording of previous events Refractory Relapse Scanning Signal Transduction Site Surface Techniques Testing Therapeutic Therapeutic Agents Tissues Toxic effect Xenograft Model base clinical translation cold agglutinins experience fluorodeoxyglucose fluorodeoxyglucose positron emission tomography genome-wide human model imaging agent imaging scientist imaging study improved in vivo in vivo evaluation molecular imaging mortality neoplastic cell new therapeutic target novel novel diagnostics novel strategies novel therapeutic intervention pomalidomide pre-clinical screening standard of care targeted agent targeted treatment theranostics translational study treatment strategy tumor

项目摘要

PROJECT SUMMARY AND ABSTRACT The primary goal of this proposal is to develop novel theranostic agents targeting CD46 for imaging and treatment of multiple myeloma (MM). CD46 is a novel therapeutic target, with a cognate antibody-drug conjugate, FOR46, now in phase 1 clinical trials. Our preliminary data demonstrate high expression of CD46 in MM. In this proposal, we develop and implement [89Zr]DFO-YS5 and [225Ac]DOTA-YS5 as imaging and therapeutic agents targeting MM. The central hypothesis of this proposal is that CD46 is an effective target for molecular imaging and therapy of MM. In this proposal we test this hypothesis in preclinical models, and in a pilot study of patients with MM. In order to test this hypothesis, we have assembled an experienced team of chemists, biologists, imaging scientists, physicists, and physicians to evaluate this method in preclinical models and in patients. In specific aim 1, we will develop [89Zr]DFO-YS5 and [225Ac]DOTA-YS5 as PET imaging and therapeutic agents for MM. In specific aim 2, we will develop new co-treatment approaches to maximize CD46 expression, and use these to augment [89Zr]DFO-YS5 PET and [225Ac]DOTA-YS5 treatment. In aim 3, we perform a pilot [89Zr]DFO-YS5 PET imaging study in patients with MM, and analyze the data to determine its sensitivity for detecting sites of disease. The methods developed in this proposal will ultimately be used to develop novel diagnostic and therapeutic approaches in MM, to help reduce morbidity and mortality for this disease.

项目总结与摘要